Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Revolution Medicines snagged $238 million through its initial public offering to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.
Summit Therapeutics plc announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA.
Funding to support GMP adenovirus manufacture for a first-in-human basket clinical trial in melanoma, lung cancer, and triple negative breast cancer
Valeritas and its subsidiaries filed for Chapter 11 bankruptcy on February 9, 2020 in the District of Delaware. At the same time, Zealand entered into the definitive deal to buy the assets.
Founded by UKI2S with co-investment from LifeArc & Parkwalk to advance a diabetic macular edema gene therapy and other pipeline products
Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units at a price of $0.20 per Unit.
Corteva, Inc. reported financial results for the quarter ended December 31, 2019 and the full year 2019.
Kezar Life Sciences, Inc. has announced the pricing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share.
Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, has announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a price to the public of $17.00 per share.
Three months after Sandoz announced it would acquire the Japanese business of Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings for $330 million, the deal has been completed.